Does holding at 1 mg for two weeks before escalating reduce early satiety?

Setup, so nobody has to ask: 1 mg · two weeks · early satiety.

I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me suspicious.

My background is quantitative but not chemical, so I can follow an equation more easily than a hand-wave.

What is the causal chain, and where does it stop being established?

two weeks at 1 mg is 14 days at one dose level — and the arithmetic the question hides is that it also moves every dose above 1 mg back by 14 days. Whether that reduces early satiety depends on which quantity it tracks. A symptom driven by the dose itself is unchanged by waiting: 1 mg is 1 mg on day 1 and on day 14. A symptom driven by the rate of change has 14 days of no change to settle in, which is the case the hold is actually made for. The distinction is testable on your own record: plot early satiety against days-since-last-increase rather than against dose, and if the peaks line up with the increases the hold is doing something. Escalation schedules are set by a prescriber, and nothing here is medical advice.

Start with the half-life, because the interval between steps should be at least four half-lives or you are escalating before the previous step has expressed itself.

The published semaglutide weight-management schedule steps 0.25, 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals, with 0.25 mg as an initiation step rather than a therapeutic one.

Label titration ladders, structure only

Structure is identical across the class: small start, four-week steps, a defined maintenance range, a defined ceiling.

Liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Hold rather than escalate while symptoms are active. Always.

The honest answer is that going slower costs time and nothing else, since the exposure ceiling is unchanged.

For an agent with a one-week half-life, steady state after a dose change is reached in about four to five weeks. Escalating at two weeks means escalating from a position you have not yet reached, and the resulting exposure is higher than the schedule intends.

Escalating while gastrointestinal symptoms are still active is the commonest avoidable error. Tolerance to the previous step has not developed, and the new step lands on top of it.

The top of the schedule is not the target. The working dose is.

The short version: four-weekly steps for the weekly agents, hold rather than escalate when symptoms are active, and slower is always available.

Titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.

Holding a step for eight weeks instead of four is a legitimate approach with no efficacy cost at the destination, and it is what the trials effectively did for anyone who tolerated poorly.

Four to five half-lives to steady state is standard first-order pharmacokinetics and gives the four-week interval directly from the one-week half-life.

Slower costs time and nothing else. The ceiling is the same.

The underlying point is that this is the single most consequential controllable variable in the whole experience, and people routinely rush it.

The published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.

Four half-lives between steps, minimum. Work it out for your agent.

On the detail: the initiation step in most schedules is not intended to be therapeutic; it is there to introduce the receptor to the drug.

The dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.

Stepping back is a normal adjustment, not a failure.